HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LFMD
LifeMD, Inc.
LFMD lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LFMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Strong |
LFMD's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LFMD PE Valuation
LFMD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LFMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
LFMD has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
LFMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$0.11 |
| Q2 2026 | -$0.04 | +$0.16 |
| Q1 2026 | $0.06 | +$0.39 |
| Q4 2025 | $0.27 | +$0.80 |
| Q3 2025 | -$0.16 | +$0.48 |
| Q2 2025 | -$0.20 | +$0.50 |
| Q1 2025 | -$0.33 | +$0.41 |
| Q4 2024 | -$0.53 | +$0.17 |
LFMD has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LFMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over LFMD on profitability, with a higher operating margin.
LFMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $44.6M | -26% |
| Q2 2026 | $47.3M | -24% |
| Q1 2026 | $50.2M | -24% |
| Q4 2025 | $7.1M | -89% |
| Q3 2025 | $60.2M | +13% |
| Q2 2025 | $62.2M | +23% |
| Q1 2025 | $65.7M | +49% |
| Q4 2024 | $64.3M | +43% |
LFMD's revenue has slid since its 2025 peak: $45M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | -6.7 points |
| Q2 2026 | -15% | -14 points |
| Q1 2026 | -18% | -22 points |
| Q4 2025 | -88% | -90 points |
| Q3 2025 | -3.3% | +5.5 points |
| Q2 2025 | -1.5% | +11 points |
| Q1 2025 | 3.9% | +18 points |
| Q4 2024 | 1.6% | +6.4 points |
LFMD's operating margin was −10% last quarter, down 6.7 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over LFMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
LFMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1M | -$176K |
| Q2 2026 | -$7M | -189% |
| Q1 2026 | $339.4K | -88% |
| Q4 2025 | -$3.4M | -356% |
| Q3 2025 | -$944.4K | -116% |
| Q2 2025 | $7.8M | +101% |
| Q1 2025 | $2.9M | -41% |
| Q4 2024 | $1.3M | -76% |
LFMD's free cash flow was −$11M over the past year, against $11M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LFMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LFMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +394K shares |
| 1 year | +4.4% | +2M shares |
| 3 years | +40% | +13.7M shares |
| 5 years | +81% | +21.5M shares |
| Available history | +387% | +38.3M shares |
LFMD has 48M diluted shares, up 4.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2025 | $270,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LFMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -9.6x | Net Cash |
LFMD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LFMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 10.1 | Oversold |
LFMD's weekly RSI is 27 (oversold) and its Stochastic is 10 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LFMD PE vs Healthcare Sector
| Metric | LFMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LFMD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LFMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.39 | 31% below |
| 20 week MA | $3.14 | 47% below |
| 50 week MA | $3.54 | 53% below |
| 100 week MA | $5.40 | 69% below |
| 200 week MA | $5.43 | 69% below |
LFMD is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over LFMD on returns for 2026, with the stronger performance.
LFMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.65 | $7.84 | +1106% |
| 2021 | $7.84 | $4.32 | -45% |
| 2022 | $4.32 | $2.05 | -53% |
| 2023 | $2.05 | $8.29 | +304% |
| 2024 | $8.29 | $5.22 | -37% |
| 2025 | $5.22 | $3.50 | -33% |
| 2026 YTD | $3.50 | $1.66 | -53% |
LFMD's yearly returns have swung widely, from +1106% in 2020 to −53% in 2022. It's down 53% so far in 2026.